Last edition
News about "Japanese patients"
Renalys Pharma Completes Patient Enrollment for Phase III Trial of Sparsentan in Japan
In April 2024 Renalys submitted an Investigational New Drug (IND) Application for sparsentan to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan.
Japanese Patients | 01/02/2025 | By Abha | 346
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members